Scientific Sessions 2024  /  Optimizing Outcomes in Atrial Fibrillation - Where Do We Go from Here?  /  Efficacy of Sacubitril-Valsartan Compared with Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker for Preventing Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Meta-Analysis
Logo

American Heart Association

  2
  0

Final ID: Mo2133

Efficacy of Sacubitril-Valsartan Compared with Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker for Preventing Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Meta-Analysis

Abstract Body (Do not enter title and authors here):
INTRODUCTION: In patients who have undergone catheter ablation due to atrial fibrillation (AF), recurrence of this condition can occur. The effect of Sacubitril/Valsartan (S/V) on preventing atrial fibrillation recurrence compared to Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor Blocker (ARB) is not established. This meta-analysis aims to establish the best therapeutic choice for preventing AF recurrence after catheter ablation.
METHOD: A systematic search was conducted in PubMed, Embase, and Cochrane databases for randomized clinical trial (RCT) and observational studies comparing the use of S/V with ACEI/ARB in patients who underwent catheter ablation. Results were presented as mean differences (MD) with a 95% confidence interval (CI). Heterogeneity was assessed by I2, and outcomes were expressed as relative risks (RR), using R software version 4.2.3.
RESULTS: Three randomized clinical trials and one cohort study, comprising 642 patients with 319 patients in the S/V group and 323 in the control group, were included. Follow-up ranged from 6 to 36 months, with mean ages ranging from 58.9 to 65.8 years. A significant reduction in persistent AF occurrence was demonstrated favoring the S/V group (RR: 0.54; 95% CI: 0.41 to 0.70; P=0.000004; I2: 80%) compared to the ACEI/ARB group. The analysis also showed a significant reduction in Left Atrial Volume Index (LAVI) (MD: -5.33; 95% CI: -8.76 to -1.90; P=0.002; I2: 57%) in the S/V group compared to ACEI/ARB. There was no significant difference in left ventricular ejection fraction (LVEF) with S/V use (MD: 1.23; 95% CI: -0.12 to 2.60; P=0.076; I2: 0%) compared to ACEI/ARB.
CONCLUSION: This meta-analysis demonstrated the efficacy of S/V in reducing the incidence of AF in patients undergoing catheter ablation compared to the use of ACEI/ARB. However, more randomized clinical trials are needed for a comprehensive evaluation of its efficacy in reducing AF recurrence in post-catheter ablation patients in clinical practice.
  • Bezerra, Fernando  ( Anhembi Morumbi University , São José dos Campos , SP , Brazil )
  • Rocha Dantas, Clara  ( Universidad de Buenos Aires , Buenos Aires , Argentina )
  • Sobreira, Luis  ( Federal University of Pará , Altamira , Brazil )
  • Kendi Tsuchiya Sano, Vitor  ( Federal University of Acre , Rio Branco , Brazil )
  • De Oliveira Macena Lobo, Artur  ( Federal University of Pernambuco , Recife , Brazil )
  • Cardoso, Jorge  ( University of Pernambuco, , Recife , Brazil )
  • Kelly, Francinny  ( Dante Pazzanese Cardiology Institute , Sao Paulo , Brazil )
  • A De Moraes, Francisco Cezar  ( Federal University of Para , Recife , Brazil )
  • Consolim Colombo, Fernanda  ( Heart Institute , Sao paulo , Brazil )
    • Author Disclosures:
    FERNANDO BEZERRA: DO NOT have relevant financial relationships | Clara Rocha Dantas: DO NOT have relevant financial relationships | Luis Sobreira: DO NOT have relevant financial relationships | Vitor Kendi Tsuchiya Sano: DO NOT have relevant financial relationships | Artur de Oliveira Macena Lobo: No Answer | Jorge Cardoso: DO NOT have relevant financial relationships | Francinny Kelly: DO NOT have relevant financial relationships | Francisco Cezar A de Moraes: No Answer | Fernanda Consolim Colombo: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Optimizing Outcomes in Atrial Fibrillation - Where Do We Go from Here?

Monday, 11/18/2024 , 01:30PM - 02:30PM

Abstract Poster Session

More abstracts on this topic:

4-5 Years Outcomes of Left Atrial Appendage Closure vs. Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis:

Khan Muhammad Aslam, Haider Taimoor, Bhattarai Shraddha, Afzal Hafsa, Khan Bilal, Muhammad Anza, Shafique Nouman, Bhatia Hitesh, Aafreen Asna, Adil Abid Nawaz Khan, Akbar Usman, Khan Alamzaib, Haider Muhammad Adnan

A novel risk score predicts the prevalence of left atrial low-voltage areas and rhythm outcome in patients undergoing long-standing persistent atrial fibrillation ablation

Ooka Hirotaka, Nakao Sho, Kusuda Masaya, Ariyasu Wataru, Kudo Satoshi, Fujii Subaru, Mano Toshiaki, Matsuda Yasuhiro, Masuda Masaharu, Okamoto Shin, Ishihara Takayuki, Nanto Kiyonori, Tsujimura Takuya, Hata Yosuke, Uematsu Hiroyuki

More abstracts from these authors:
Efficacy and Safety of Radiofrequency-Based Renal Denervation on Resistant Hypertensive Patients: A Systematic Review and Meta-Analysis

Sobreira Luis, Rocha Dantas Clara, Bezerra Fernando, Tsuchiya Sano Vitor, De Oliveira Macena Lobo Artur, Cardoso Jorge, Kelly Francinny, A De Moraes Francisco Cezar, Consolim Colombo Fernanda

Comparison of the Risk of Cardiovascular Disease Between Degarelix Versus Gonadotropin-Releasing Hormone Agonists: a Systematic Review and Meta-Analysis

Hoffmeister Nathalia, Rocha Dantas Clara, Kelly Francinny, De Oliveira Macena Lobo Artur, Menegaz De Almeida Artur, Kendi Tsuchiya Sano Vitor, A De Moraes Francisco Cezar

4143120_File000000.jpg
4143120_File000000.jpg
4143120_File000001.jpg
4143120_File000001.jpg
You have to be authorized to contact abstract author. Please, Login
Not Available